arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

IDEXX LABORATORIES INC /DE

IDXX
$590.17 ▲ +5.48 (+0.94%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
19 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
86
Health
Excellent
Bullish
auto_awesome

Analytical Summary

IDEXX LABORATORIES INC /DE shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $47.5B
Dividend Yield
Revenue Growth 10.4%
Op. Margin 31.6%
ROIC 52.9%
FCF / Share $13.14
Trailing P/E 44.8x
Price / Book 29.3x
FCF Yield 2.2%
Debt / Equity 0.28
info Valuation on last close. End-of-day price, Aug 6, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.30B
↑ +10.4%
Net Income Profit after all expenses
$1.06B
↑ +19.3%
Operating Margin Operating profit as % of sales
31.6%
↑ +9.2% 88th
FCF / Share Free cash flow per share
$13.14
↑ +34.1%
Long-Term Debt Long-term obligations
$450.00M
↓ -27.2%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
87
Returns
98
Financial Health
79
Cash Quality
65

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 71 quarters